Dr. Zamiri is a clinician-scientist who specializes in ophthalmology.
She comes to Graybug after a tenure at Novartis Pharmaceuticals, where she was vice president, global head of clinical development, and therapeutic area head for ophthalmology. At Novartis she led a group of clinical scientists and ophthalmologists.
“I am excited about Graybug’s sustained ocular delivery technologies and their potential to alleviate the treatment burden while delivering better clinical outcomes for patients with vision-threatening diseases like wet [macular degeneration],” said Dr. Zamiri.
More articles on surgery centers:
4 COVID-19 supply considerations for ASCs
5 hospitals, health systems opening or planning ASCs
ASCs reopening to patients: Check these 7 boxes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.